2-(3-(三氟甲基)苯基)哌啶 | 383128-75-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 2-(3-(三氟甲基)苯基)哌啶
• 英文名称: (+/-)-2-(3-trifluoromethylphenyl)-piperidine
• 英文别名: 2-[3-(Trifluoromethyl)phenyl]piperidine
• CAS: 383128-75-4
• 化学式: C₁₂H₁₄F₃N
• mdl: MFCD02663670
• 分子量: 229.245
• InChiKey: LNGYJPKFIYPWIT-UHFFFAOYSA-N

物化性质

• 沸点：
  255.5±40.0 °C(Predicted)
• 密度：
  1.145±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  2-(3-(三氟甲基)苯基)哌啶 在 N-氯代丁二酰亚胺 、 potassium hydroxide 作用下， 以 乙醚 、 乙醇 为溶剂， 生成
  参考文献：
  名称：

  钯催化环内 1-氮杂烯丙基阴离子的烯丙基化

  摘要：

  环内 1-氮杂烯丙基阴离子在钯催化的烯丙基化中与乙酸烯丙酯结合，然后还原，得到未保护的 2-（杂）芳基-3-烯丙基哌啶和 2-烯丙基-3-芳基吗啉，这些产品不易通过其他方式获得。然后烯丙基很容易转化成各种官能团。使用对映体纯的 BI-DIME 型配体对反应的不对称变体进行的初步研究表明，产物具有中等的对映选择性。计算研究表明，内层还原消除和外层亲核取代的能垒几乎相同，这使得它们都是可能的反应途径。此外，内球机制显示出对映体区别性的C-C键形成步骤，而外球机制的选择性要低得多，这两者结合起来使反应的不对称变体具有中等对映选择性。

  DOI：

  10.1021/acs.joc.4c00743
• 作为产物：
  描述：

  1-Boc-2-哌啶酮 在 sodium tetrahydroborate 、 碘 、 magnesium 、 三氟乙酸 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 3.0h， 生成 2-(3-(三氟甲基)苯基)哌啶
  参考文献：
  名称：

  A One-Pot Process for the Enantioselective Synthesis of Amines via Reductive Amination under Transfer Hydrogenation Conditions

  摘要：

  Cyclic amines may be prepared via a sequence of deprotection followed by intramolecular reductive amination of t-Boc-protected amino ketones under asymmetric transfer hydrogenation conditions. In cases where the corresponding imine reaction proceeds with high enantioselectivity, this is reflected in the one-step process.

  DOI：

  10.1021/ol035746r

文献信息

• [EN] BENZOXAZEPINES AS INHIBITORS OF PI3K/m TOR AND METHODS OF THEIR USE AND MANUFACTURE<br/>[FR] BENZOXAZÉPINES COMME INHIBITEURS DE PI3K/M TOR, MÉTHODES D'UTILISATION ET DE FABRICATION BENZOXAZEPINES AS INHIBITORS OF PI3K/M TOR AND METHODS OF THEIR USE AND MANUFACTURE
  申请人：EXELIXIS INC

  公开号：WO2010138487A1

  公开（公告）日：2010-12-02

  The invention is directed to Compounds of Formula (I): the invention provides compounds that inhibit, regulate, and/or modulate P13K and/or mTOR that are useful in the treatment of hyperproliferative diseases, such as cancer, in mammals. This invention also provides methods of making the compound methods of using such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and to pharmaceutical compositions containing such compounds. For example, cancer in which activity against PI3fC-alph mTOR, or both contributes to its pathology and/or symptomatology include breast cancer mantle cell lymphoma, renal cell carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, NPM/ALK- transformed anaplastic large cell lymphoma, diffu large B cell lymphoma, rhabdomyosarcoma, ovarian cancer, endometrial cancer, cervic cancer, non small cell lung carcinoma, small cell lung carcinoma, adenocarcinoma, col cancer, rectal cancer, gastric carcinoma, hepatocellular carcinoma, melanoma, pancreat cancer, prostate carcinoma, thyroid carcinoma, anaplastic large cell lymphoma, hemangiom glioblastoma, or head and neck cancer.

  这项发明涉及式(I)的化合物：该发明提供了抑制、调节和/或调节P13K和/或mTOR的化合物，这些化合物在治疗哺乳动物的高增殖性疾病，如癌症，方面非常有用。该发明还提供了制备该化合物的方法，以及在治疗哺乳动物，特别是人类的高增殖性疾病中使用这些化合物的方法，以及含有这些化合物的药物组合物。例如，对PI3fC-α mTOR或两者都具有活性有助于其病理学和/或症状学的癌症包括乳腺癌、套细胞淋巴瘤、肾细胞癌、急性髓细胞白血病、慢性髓细胞白血病、NPM/ALK转化的间变性大细胞淋巴瘤、弥漫性大B细胞淋巴瘤、横纹肌肉瘤、卵巢癌、子宫内膜癌、宫颈癌、非小细胞肺癌、小细胞肺癌、腺癌、结肠癌、直肠癌、胃癌、肝细胞癌、黑色素瘤、胰腺癌、前列腺癌、甲状腺癌、间变性大细胞淋巴瘤、血管瘤、胶质母细胞瘤或头颈癌。
• Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
  申请人：Aay Naing

  公开号：US20120258953A1

  公开（公告）日：2012-10-11

  The invention is directed to Compounds of Formula (I): the invention provides compounds that inhibit, regulate, and/or modulate P13K and/or mTOR that are useful in the treatment of hyperproliferative diseases, such as cancer, in mammals. This invention also provides methods of making the compound methods of using such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and to pharmaceutical compositions containing such compounds. For example, cancer in which activity against PI3fC-alph mTOR, or both contributes to its pathology and/or symptomatology include breast cancer mantle cell lymphoma, renal cell carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, NPM/ALK-transformed anaplastic large cell lymphoma, diffu large B cell lymphoma, rhabdomyosarcoma, ovarian cancer, endometrial cancer, cervic cancer, non small cell lung carcinoma, small cell lung carcinoma, adenocarcinoma, col cancer, rectal cancer, gastric carcinoma, hepatocellular carcinoma, melanoma, pancreat cancer, prostate carcinoma, thyroid carcinoma, anaplastic large cell lymphoma, hemangiom glioblastoma, or head and neck cancer.

  本发明涉及化合物I式的化合物：本发明提供了一种抑制、调节和/或调节P13K和/或mTOR的化合物，其在哺乳动物中治疗增殖过度性疾病，如癌症方面非常有用。本发明还提供了制备该化合物的方法，使用这些化合物在哺乳动物中治疗增殖过度性疾病的方法，特别是人类，并提供了包含这些化合物的制药组合物。例如，对于活性针对PI3fC-alph mTOR或两者都对其病理和/或症状学产生贡献的癌症，包括乳腺癌、曼托细胞淋巴瘤、肾细胞癌、急性髓性白血病、慢性髓性白血病、NPM / ALK转化的间变性大细胞淋巴瘤、弥漫性大B细胞淋巴瘤、横纹肌肉瘤、卵巢癌、子宫内膜癌、宫颈癌、非小细胞肺癌、小细胞肺癌、腺癌、结肠癌、直肠癌、胃癌、肝细胞癌、黑色素瘤、胰腺癌、前列腺癌、甲状腺癌、间变性大细胞淋巴瘤、血管瘤、胶质母细胞瘤或头颈癌。
• BENZOXAZEPINES AS INHIBITORS OF PI3K/m TOR AND METHODS OF THEIR USE AND MANUFACTURE
  申请人：Exelixis, Inc.

  公开号：EP2435426A1

  公开（公告）日：2012-04-04
• BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE
  申请人：Exelixis, Inc.

  公开号：EP2640367A2

  公开（公告）日：2013-09-25
• US8637499B2
  申请人：——

  公开号：US8637499B2

  公开（公告）日：2014-01-28